Admixtures of Chemotherapy Agents by Continuous Infusion
The application of multiple drugs or combination chemotherapy for the treatment of cancer has become standard practice since its introduction in the 1960s for the treatment of first testicular cancer and subsequently leukemias and Hodgkin’s disease. Today chemotherapy for malignancies virtually always entails the application of multiple agents, either simultaneously or in some planned sequence. The rationale for combination chemotherapy is based upon the concept of affecting multiple metabolic sites within the tumor cell or multiple points during the tumor cell cycle. At a practical level, the use of non-cross-resistant agents without overlapping toxicity maximizes the effectiveness of such combinations. Recent conceptual advances in the application of cancer chemotherapy have introduced the concept of alternating non-cross-resistant agents applied intensively on a weekly basis. Another conceptual development has been the application of biochemical modulation utilizing a noncytotoxic enhancing agent in conjunction with a primary cytotoxic drug.
KeywordsDose Rate Testicular Cancer Multiple Agent Infusion Chemotherapy Biochemical Modulation
Unable to display preview. Download preview PDF.
- Anderson N, Wallach S, Lokich J et al. (1989b) VP16–213 + cisplatinum: 72 hour continuous admixed infusion in 94 patients. ASCO Abs.Google Scholar
- Kish J, Eusley J, Weaver A et al. (1984) Superior response rate with 96 hours 5FU infusion vs 5FU bolus. PASCO Abs. C-695Google Scholar
- Legha SS, Benjamin RS, MacKay B et al. (1982) Role of Adriamycin in breast cancer and sarcomas. In: Muggia FM, Young CW, Carter SK (eds) Anthracycline antibiotics in cancer therapy. Nijhoff, The Hague, pp 432–434Google Scholar
- Lokich J (1986) Protracted infusional chemotherapy. In: Lokich J (ed) Cancer chemotherapy by infusion. Precept, Chicago, pp 243–264Google Scholar
- Rosenthal J, Adriamycin and bleomycin combination admixture administered by continuous IV infusion alone and concomitantly with radiation therapy. (Protocol activated at Downstate 1988).Google Scholar